贝那普利在慢性肾小球肾炎患者体内的药动学被引量：7

Pharmacokinetics of benazepril hydrochloride tablet in chronic glomerulonephritis patients

导出

摘要目的:探讨贝那普利在慢性肾小球肾炎患者体内药动学的变化。方法:30例慢性肾小球肾炎患者口服20 mg贝那普利后,采用高效液相色谱-串联质谱法(HPLC-MS/MS)检测受试者血浆中内那普利和其代谢物依那普利拉的浓度,并计算主要药动学参数。结果:慢性肾小球肾炎患者贝那普利主要药动学参数血药浓度-时间曲线下面积(AUC0-t)为(72.9±30.5)μg.h.L-1,AUC0-∞为(80.9±12.8)μg.h.L-1,最大血药浓度为(75.8±1.6)μg.L-1,达峰时间为(0.81±0.12)h。贝那普利拉:AUC0-t为(358.3±81.2)μg.h.L-1,AUC0-∞为(402.2±23.4)μg.h.L-1,Cmax为(48.5±7.7)μg.L-1,tmax为(2.01±0.45)h。结论:本实验为贝那普利治疗慢性肾小球肾炎患者临床用药具有重要的指导意义。 OBJECTIVE To explore the pharmacokinetics of benazepril hydrochloride tablet in chronic glomerulonephritis pa- tients. METHODS Benazepril hydrochloride tablets were given to 30 chronic glomerulonephritis patients of a dose of 20 mg, the concentrations of benazepril and benazeprilat the essential active metabolite of benazepril were analyzed by HPLC-MS/MS. The main pbarmacokinetic parameters were calculated. RESULTS The main pharmacokinetic parameters of benazepril were as the follows ： AUC_0-t was （72. 9 ±30. 5） μg. h. L-1 , AUC_0-∞ was （80. 9 ±12.8） μg. h. L-1 , C_max was （ 75.8 ±1.6 ） μg. L-1 , t was （0.81± 0. 12） h. The main pharmacokinetic parameters of benazeprilat were as follows： AUC0 , was （358.3± 81.2） μg.h. L^-1, AUC0-∞,was （402.2±23.4） μg-h.L -1, C_max was （48.5±7.7） μg.L^-1, t were （2.01 ±0.45） h. CONCLUSION The study could provide reference for clinical rational administration of benazepril hydrochloride tablet in chronic glomerulonephritis patients.

作者沙士义

机构地区枣庄市立医院药剂科

出处《中国医院药学杂志》 CAS CSCD 北大核心 2013年第2期128-131,共4页 Chinese Journal of Hospital Pharmacy

关键词贝那普利慢性肾小球肾炎药动学 benazepril benazeprilat chronic glomerulonephritis pharmacokinetics

分类号 R969.1 [医药卫生—药理学]

引文网络
相关文献

参考文献7

1Mou S,Wang Q,Li J. Urinary excretion of liver type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis[J].Clinica Chimica Acta,2012,(1-2):187-191.
2Chebotareva NV,Bobkova IN,Kozlovskaia LV. Estimation of podocyte dysfunction by nephrinuria severity in proteinuric forms of chronic glomerulonephritis[J].Terapevticheskii Arkhiv,2011,(06):18-23.
3方一卿,鲁盈,王永钧,殷佳珍,涂晓,朱斌,袁博寒,陈佳韵,陈洪宇,周柳沙,毛俐婵,崔杏成,王旭强,张敏鸥,俞东容,王宇辉,童孟立,程晓霞.苯那普利联合祛风除湿中药治疗慢性肾脏病3期风湿内扰证的前瞻性研究[J].中国中西医结合杂志,2012,32(3):311-316. 被引量：22
4Pilli NR,Inamadugu JK,Mullangi R. Simultaneous determination of atorvastatin,amlodipine,ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study[J].Biomedical Chromatography,2011,(04):439-449.
5俞小凤.贝那普利联合不同药物治疗慢性肾小球肾炎疗效观察[J].现代中西医结合杂志,2011,20(10):1204-1205. 被引量：32
6Barrios V,Escobar C. Antihypertensive and organ-protective effects of benazepril[J].Expert Review of Cardiovascular Therapy,2010,(12):1653-1671.
7Xiao W,Chen B,Yao S. Simultaneous determination of benazepril hydrochloride and benazeprilat in plasma by high-performance liquid chromatography/electrospray-mass spectrometry[J].Journal of Chromatography B:Analytical Technologies in the Biomedical and Life Sciences,2005,(02):303-308.

二级参考文献17

1陈洪宇,朱彩凤,张敏鸥,陈长江,王永钧.IgA肾病继发局灶节段性肾小球硬化与中医虚、瘀、风湿的相关性——附182例临床病理与中医证候学分析[J].中国中西医结合肾病杂志,2005,6(9):514-519. 被引量：23
2张敏鸥,王永钧,陈洪宇,朱采凤.中西医结合个体化联合序贯方案治疗中重型IgA肾病的临床研究[J].中国中医药科技,2005,12(6):338-340. 被引量：7
3唐长江.苯那普利延缓慢性肾功能衰竭进展的临床观察[J].临床和实验医学杂志,2007,6(9):58-59. 被引量：2
4Piccoli GB. Patient-based continuum of care in nephrology: why read Thomas Addis" Glomerular Nephritis" in 20107 [ J]. J Nephrol,2010,23 (2) :164 - 167.
5Bakris GL,Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events ( ACCOMPLISH ) : a prespecifled secondary analysis of a randomised controlled trial[ J]. Lancet, 2010,375(9721 ) :1173 - 1181.
6Bramlage P. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension [ J ]. Expert Opin Pharmacother, 2009,10 (11) :1755 - 1767.
7Hail N Jr, Chen P,Bushman LR. Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention [ J ]. N eoplasia, 2010 , 12 ( 6 ) : 464 - 475.
8Xie Y,Chen X. Epidemiology, major outcomes,risk factors, prevention and management of chronic kidney disease in China[J]. Am J Nephrol,2008,28 ( 1 ) : 1 - 7.
9王海燕,王梅译.慢性肾脏病及透析的临床实践指南-附述评[M].北京:人民卫生出版社,2003:1-275.
10Chan TM,Li FK,Tang CS,et al.Efficacy of mycopheno-late mofetil in patients with diffuse proliferative lupus ne-phritis[J].N Engl J Med,2000,343(16):1156-1162.